OS Therapies Incorporated (OSTX)
| Market Cap | 75.05M +66.9% |
| Revenue (ttm) | n/a |
| Net Income | -35.27M |
| EPS | -1.05 |
| Shares Out | 44.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,609 |
| Open | 1.710 |
| Previous Close | 1.690 |
| Day's Range | 1.710 - 1.730 |
| 52-Week Range | 1.150 - 2.570 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 9.40 (+457.86%) |
| Earnings Date | May 18, 2026 |
About OSTX
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company’s pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and i... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for OSTX stock is "Strong Buy." The 12-month stock price target is $9.4, which is an increase of 457.86% from the latest price.
News
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the U.S. and Conditional MAA in the U.K., Europe and Australia Patent pending pharmacodynamic response b...
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs.
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the prevention or delay of recurrence in fully-resected pulmonary metastatic osteosarc...
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences
ASCO 2026: 2.5-Year Overall Survival Data Jefferies Healthcare Conference: Partnering & Investor meetings BIO International Convention: Panel Participation MIB Agents Factor Osteosarcoma Conference: D...
OS Therapies price target lowered to $13 from $14 at Lake Street
Lake Street lowered the firm’s price target on OS Therapies (OSTX) to $13 from $14 and keeps a Buy rating on the shares following the company’s Q1 update. 2.5-year overall…
OS Therapies Quarterly report: Q1 2026
OS Therapies has published its Q1 2026 quarterly earnings report on May 18, 2026.
OS Therapies Earnings release: Q1 2026
OS Therapies released its Q1 2026 earnings on May 18, 2026, summarizing the period's financial results.
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 $4.5 million of accrued VAT refunds ...
OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026
New York, New York and Rockville, Maryland--(Newsfile Corp. - May 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-base...
OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor
Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S., U.K, Europe and Australia in anticipation of ...
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX)
Dallas, Texas--(Newsfile Corp. - May 12, 2026) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage on OS Therapies Inc. (NYSE American: OSTX). OS Therapies adv...
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data and review regulatory successes validating ...
OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET
Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetings Remaining Q2-2026 regulatory meetings include two U.S. FDA meetings and one UK MHRA meeting, in addition to follow-up meet...
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes
New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responses Company to host conference cal...
OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor
Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on driving innovation for human health Will assist with lister...
OS Therapies Appoints Craig Eagle, MD as Strategic Advisor
Senior leadership roles at Guardant Health, Genentech and Pfizer Regulatory, clinical and commercial expertise in therapeutics and biomarkers Will assist with osteosarcoma regulatory advice and oncolo...
OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors
Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26 Company expects to receive approximately $2 million in non-dilutive R&D tax credits repa...
OS Therapies price target lowered to $14 from $17 at Lake Street
Lake Street lowered the firm’s price target on OS Therapies (OSTX) to $14 from $17 and keeps a Buy rating on the shares. The firm, which notes that OS “aggressively…
OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update
December 2025 Type C Meeting confirmed immune biomarkers suitability to establish surrogate clinical efficacy that could support BLA under Accelerated Approval Pathway Pre-specified clinical outcomes ...
OS Therapies Earnings release: Q4 2025
OS Therapies released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
OS Therapies Annual report: Q4 2025
OS Therapies has published its Q4 2025 annual report on March 31, 2026.
OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma
Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with expected Phase 3 commencement in the third quarter of 2026 initially in Australia Commencing the Phase...
OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma
ATMP benefits include access to the Conditional Marketing Authorisation accelerated market access pathway in Europe, significantly reduced user fees for small and medium-sized enterprises (SMEs), tail...
OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussions OS Therapies on track to complete clinical data submission by the end of Q1 2026 Ne...
OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma
Additional forthcoming biomarker data from human trial expected to further characterize immune pathway activation and its relationship to clinical outcomes U.S., U.K. and European osteosarcoma key opi...